middle.news
TrivarX appoints new CEO and secures product supply for Stabl-Im trial
2:02pm on Tuesday 28th of July, 2026 AEST
•
Healthcare Technology
Read Story
TrivarX appoints new CEO and secures product supply for Stabl-Im trial
2:02pm on Tuesday 28th of July, 2026 AEST
Key Points
Dr Danielle Meyrick appointed CEO with clinical and regulatory expertise
Contract research organisation Beyond Drug Development engaged for Phase 1 trial
Investigational product supply secured post-quarter to enable trial start
Phase 1 trial to assess safety and imaging feasibility in healthy volunteers and oncology
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Trivarx (ASX:TRI)
OPEN ARTICLE